Evicenter
MarkdownMedical informationP&T meetings
Darovasertib (IDE196)

First-line metastatic uveal melanoma, in combination with crizotinib

Also known as LXS196
Manufacturer
IDEAYA Biosciences
Launch
Not announced
Last updated
206 sources

Clinical evidence

OptimUM-01

88 evidence topics · 12 sources

Objective
Location and study date
Registry study dates
Study characteristicQuoted record
Study start (actual)“2019-06-28”
Primary completion (estimated)“2027-01-29”
Study completion (estimated)“2027-06-15”
First-line cohort publication: enrolling centers
CountryQuoted institution
United States“Sarah Cannon Research Institute Nashville, TN”
United States“MD Anderson, Houston, TX”
United States“Thomas Jefferson University Hospital, Philadelphia, PA”
United States“Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA”
United States“Duke University Medical Center, Durham, NC”
United States“California Pacific Medical Center Research Institute, San Francisco, CA”
United States“University of Cincinnati Medical Center, Cincinnati, OH”
United States“Cancer and Hematology Centers of Western Michigan, Grand Rapids, MI”
United States“Cleveland Clinic, Cleveland, OH”
United States“Sarah Cannon Research Institute at Healthone Denver, Denver, CO”
United States“Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA”
United States“Honor Health Research Institute, Scottsdale, AZ”
United States“Florida Cancer Specialist—North, FL”
United States“Florida Cancer Specialist—South, FL”
United States“St Joseph Mosaic Life Care, St Joseph, MO”
United States“Goshen Health Center for Cancer Care, Goshen, IN”
United States“Columbia University Medical Center, New York Presbyterian Hospital, New York, NY”
United States“The University of Texas MD Anderson Cancer Center, TX”
Australia“Westmead and Blacktown Hospitals, University of Sydney and Melanoma Institute Australia”
Australia“University of Queensland, Brisbane”
Canada“Princess Margaret Cancer Centre, Departments of Medicine and Immunology, University of Toronto, Toronto”
Study design
Registry design: nonrandomized, open-label, sequential assignment
Study characteristicQuoted record
Other study ID number“IDE196-001”
Primary purpose“Treatment”
Allocation“Non-Randomized”
Interventional model“Sequential Assignment”
Masking“None (Open Label)”
Eligibility criteria
Inclusion criteria, including documentation required for treatment-naive HLA-A∗02:01-positive participants
Treatment
Study outcomes
Rationale for using RECIST v1.1 objective response rate as the primary endpoint
Registry primary outcomes
Statistical analysis description
Number of participants (Planned and analyzed)
Registry: estimated enrollment
Study characteristicQuoted record
Enrollment (estimated), all cohorts of the basket study“336”
Description of analysis sets
Results
Participant disposition
Baseline characteristics
First-line cohort: baseline characteristics of 44 participants
CharacteristicFirst-line cohort, N = 44
Age, median years (range)“64.5 (21, 80)”
Age less than 65 years, No. (%)“22 (50.0)”
Female, No. (%)“21 (47.7)”
Male, No. (%)“23 (52.3)”
Race White, No. (%)“41 (93.2%)”
Race Asian, No. (%)“1 (2.3%)”
Race other or not reported, No. (%)“2 (4.5%)”
ECOG PS 0, No. (%)“27 (61.4)”
ECOG PS 1, No. (%)“17 (38.6)”
Baseline LDH normal, No. (%)“29 (65.9)”
Baseline LDH above ULN, No. (%)“14 (31.8)”
Baseline LDH more than 2× ULN, No. (%)“7 (15.9)”
Largest metastatic lesion 3.0 cm or less, No. (%)“24 (54.5)”
Largest metastatic lesion 3.1 to 8.0 cm, No. (%)“15 (34.1)”
Largest metastatic lesion 8.1 cm or more, No. (%)“4 (9.1)”
Metastases hepatic only, No. (%)“23 (52.3)”
Metastases extrahepatic only, No. (%)“2 (4.5)”
Metastases hepatic and extrahepatic, No. (%)“18 (40.9)”
HLA-A∗02:01 negative, No. (%)“30 (68.2)”
HLA-A∗02:01 positive, No. (%)“12 (27.3)”
HLA-A∗02:01 unknown, No. (%)“2 (4.5)”
HLA-A∗02:01-positive expansion: baseline characteristics of treatment-naive and overall populations
CharacteristicTreatment-naive, N = 13Overall, N = 101
Age, median years (range)“65.0 (21, 81)”“66.0 (21, 81)”
Female, n (%)“7 (53.8)”“44 (43.6)”
Race White, n (%)“13 (100.0)”“95 (94.1)”
ECOG PS 0, n (%)“6 (46.2)”“66 (65.3)”
ECOG PS 1, n (%)“7 (53.8)”“35 (34.7)”
Baseline LDH at or below ULN, n (%)“7 (53.8)”“36 (35.6)”
Baseline LDH above ULN and below 2× ULN, n (%)“4 (30.8)”“43 (42.6)”
Baseline LDH 2× ULN or higher, n (%)“2 (15.4)”“22 (21.8)”
Metastases hepatic only, n (%)“8 (61.5)”“51 (50.5)”
Metastases extrahepatic only, n (%)“2 (15.4)”“12 (11.9)”
Metastases hepatic and extrahepatic, n (%)“3 (23.1)”“38 (37.6)”
No prior lines of therapy, n (%)“13 (100)”“13 (12.9)”
Prior lines of therapyOverall, N = 101, n (%)
One prior line of therapy“20 (19.8)”
Two or more prior lines of therapy“67 (66.3)”
Not recorded, previously treated“1 (1.0)”
Efficacy results
First-line cohort, efficacy-evaluable population of 41 participants: response, duration of response, and disease control
OutcomeFirst-line cohort, N = 41
Objective response rate, No. (%)“14 (34.1)”
Objective response rate, 95% CI“20.1 to 50.6”
Best overall response CR, No. (%)“0 (0.0)”
Best overall response PR, No. (%)“14 (34.1)”
Best overall response SD, No. (%)“23 (56.1)”
Best overall response PD, No. (%)“4 (9.8)”
Duration of response, median months“9.0”
Duration of response, 95% CI“3.8 to 12.0”
Time to response, median months“2.0”
Disease control rate at 8 weeks, No. (%)“37 (90.2)”
Disease control rate at 8 weeks, 95% CI“76.9 to 97.3”
Disease control rate at 26 weeks, No. (%)“22 (53.7)”
Disease control rate at 26 weeks, 95% CI“37.4 to 69.3”
First-line cohort: confirmed response by HLA-A∗02:01 status
OutcomeHLA-A∗02:01 positive, n = 10HLA-A∗02:01 negative, n = 29
Objective response rate, No. (%)“3 (30.0)”“9 (31.0)”
Objective response rate, 95% CI“3.7 to 65.2”“15.3 to 50.8”
Best overall response PR, No. (%)“3 (30.0)”“9 (31.0)”
Best overall response SD, No. (%)“7 (70.0)”“16 (55.2)”
Best overall response PD, No. (%)“0 (0.0)”“4 (13.8)”
Disease control rate, No. (%)“10 (100.0)”“25 (86.2)”
Disease control rate, 95% CI“NA”“68.3 to 96.1”
Duration of response, median months“10.15”“9.03”
Duration of response, 95% CI“3.75 to NE”“1.94 to 9.03”
Time to response, median months“3.7”“1.9”
First-line cohort: response by baseline LDH
OutcomeLDH at or below ULN, n = 28LDH above ULN to 2× ULN, n = 7LDH above 2× ULN, n = 6
Objective response rate, No. (%)“8 (28.6)”“2 (28.6)”“4 (66.7)”
Objective response rate, 95% CI“13.2 to 48.7”“3.7 to 71.0”“22.3 to 95.7”
Best overall response SD, No. (%)“17 (60.7)”“4 (57.1)”“2 (33.3)”
Best overall response PD, No. (%)“3 (10.7)”“1 (14.3)”“0 (0.0)”
Disease control rate, No. (%)“25 (89.3)”“6 (85.7)”“6 (100)”
First-line cohort: response by tumor burden (largest metastatic lesion)
Outcome3 cm or less, n = 23Above 3 cm to 8 cm, n = 15Above 8 cm, n = 3
Objective response rate, No. (%)“9 (39.1)”“4 (26.7)”“1 (33.3)”
Objective response rate, 95% CI“19.7 to .61.5”“7.8 to 55.1”“0.8 to 90.6”
Best overall response SD, No. (%)“14 (60.9)”“7 (46.7)”“2 (66.7)”
Best overall response PD, No. (%)“0 (0.0)”“4 (26.7)”“0 (0.0)”
Disease control rate, No. (%)“23 (100.0)”“11 (73.3)”“3 (100.0)”
HLA-A∗02:01-positive expansion: response, progression-free survival, and overall survival in treatment-naive and overall populations
OutcomeTreatment-naive, N = 13Overall, N = 101
Objective response rate, n/N (%)“4/11 (36.4)”“19/86 (22.1)”
Objective response rate, 95% CI“10.9, 69.2”“13.9, 32.3”
Confirmed best overall response CR, n/N (%)“0/11 (0.0)”“0/86 ( 0.0)”
Confirmed best overall response SD, n/N (%)“6/11 (54.5)”“49/86 (57.0)”
Confirmed best overall response PD, n/N (%)“0/11 (0.0)”“9/86 (10.5)”
Confirmed best overall response not evaluable, n/N (%)“1/11 (9.1)”“9/86 (10.5)”
Disease control rate, n/N (%)“10/11 (90.9)”“69/86 (80.2)”
Median progression-free survival, 95% CI“3.6, 19.6”“3.7, 6.8”
Median overall survival, 95% CI“8.9, NE”“9.8, 26.3”
HLA-A∗02:01-positive expansion: second-line participants after tebentafusp
OutcomePrior tebentafusp (second line), N = 15
Objective response rate, n/N“(5/14)”
Objective response rate, 95% CI“12.8-64.9”
Disease control rate, %“85.7%”
Disease control rate, n/N“(12/14)”
Median duration of response“5.6 mos”
Median progression-free survival, 95% CI“3.65-NE”
Median overall survival, 95% CI“9.79-NE”
HLA-A∗02:01-negative participants of OptimUM-01 as reported for comparison in the HLA-A∗02:01-positive expansion poster
OutcomeHLA-A∗02:01 negative, treatment-naive, N = 29HLA-A∗02:01 negative, overall, N = 61
Objective response rate, n/N (%)“9/29 (31.0)”“16/61 (26.2)”
Objective response rate, 95% CI“15.3, 50.8”“15.8, 39.1”
Disease control rate, n/N (%)“25/29 (86.2)”“53/61 (86.9)”
Median progression-free survival, 95% CI“3.7, 9.2”“5.0, 7.8”
Median overall survival, 95% CI“12.0, 23.8”“11.7, 20.7”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
First-line cohort: treatment-emergent adverse event summary
Adverse eventAll grades, No. (%)Grade 3 or higher, No. (%)
Any AE“44 (100)”“23 (52.3)”
Serious AE“9 (20.5)”“8 (18.2)”
AE leading to discontinuation“3 (6.8)”“1 (2.3)”
AEs related to darovasertib leading to reduction“3 (6.8)”“0”
AEs related to crizotinib leading to reduction“4 (9.1)”“1 (2.3)”
Diarrhea“42 (95.5)”“1 (2.3)”
Nausea“37 (84.1)”“0”
Edema peripheral“27 (61.4)”“0”
Vomiting“23 (52.3)”“0”
Dermatitis acneiform“20 (45.5)”“0”
Hypoalbuminemia“19 (43.2)”“1 (2.3)”
Fatigue“18 (40.9)”“0”
Constipation“13 (29.5)”“1 (2.3)”
Dizziness“13 (29.5)”“1 (2.3)”
Decreased appetite“11 (25.0)”“0”
Alanine aminotransferase increased“9 (20.5)”“2 (4.5)”
Headache“9 (20.5)”“0”
Aspartate aminotransferase increased“8 (18.2)”“1 (2.3)”
Cough“8 (18.2)”“0”
Dyspnea“8 (18.2)”“0”
Hypophosphatemia“8 (18.2)”“0”
Hypotension“8 (18.2)”“1 (2.3)”
Anemia“7 (15.9)”“0”
Blood alkaline phosphatase increased“7 (15.9)”“0”
Dysgeusia“7 (15.9)”“0”
Blood creatinine increased“6 (13.6)”“0”
COVID-19“6 (13.6)”“0”
Generalized edema“6 (13.6)”“1 (2.3)”
Hypokalemia“6 (13.6)”“2 (4.5)”
Pruritus“6 (13.6)”“0”
Rash maculopapular“6 (13.6)”“0”
Vision blurred“6 (13.6)”“2 (4.5)”
Blood lactate dehydrogenase increased“5 (11.4)”“0”
Cancer fatigue“5 (11.4)”“0”
Face edema“5 (11.4)”“0”
Gastroesophageal reflux disease“5 (11.4)”“0”
Iron deficiency anemia“5 (11.4)”“3 (6.8)”
Periorbital edema“5 (11.4)”“0”
First-line cohort: treatment-related adverse event summary
Adverse eventAll grades, No. (%)Grade 3 or higher, No. (%)
Treatment-related AE“43 (97.7)”“12 (27.3)”
Treatment-related serious AE“4 (9.1)”“3 (6.8)”
Treatment-related AE leading to discontinuation“2 (4.5)”“1 (2.3)”
Diarrhea“40 (90.9)”“1 (2.3)”
Nausea“35 (79.5)”“0”
Edema peripheral“27 (61.4)”“0”
Vomiting“21 (47.7)”“0”
Dermatitis acneiform“19 (43.2)”“0”
Hypoalbuminemia“19 (43.2)”“1 (2.3)”
Fatigue“17 (38.6)”“0”
Dizziness“12 (27.3)”“1 (2.3)”
Decreased appetite“8 (18.2)”“0”
Hypotension“8 (18.2)”“1 (2.3)”
Constipation“7 (15.9)”“0”
Aspartate aminotransferase increased“6 (13.6)”“0”
Dysgeusia“6 (13.6)”“0”
Rash maculopapular“6 (13.6)”“0”
Alanine aminotransferase increased“5 (11.4)”“1 (2.3)”
Anemia“5 (11.4)”“0”
Blood alkaline phosphatase increased“5 (11.4)”“0”
Face edema“5 (11.4)”“0”
Generalized edema“5 (11.4)”“0”
Hypophosphatemia“5 (11.4)”“0”
Periorbital edema“5 (11.4)”“0”
Pruritus“5 (11.4)”“0”
First-line cohort: treatment-emergent serious adverse events
Serious adverse eventOverall population, N = 44, No. (%)
Any serious adverse event“9 (20.5)”
Ascites“1 (2.3)”
Bacteremia“1 (2.3)”
Cancer pain“1 (2.3)”
Cholecystitis“1 (2.3)”
Diarrhea“1 (2.3)”
Fall“1 (2.3)”
Generalized edema“1 (2.3)”
Pulmonary embolism (listed in two rows of the source table)“1 (2.3)”
Pancreatitis acute“1 (2.3)”
Sudden death“1 (2.3)”
First-line cohort: treatment-related serious adverse events
Serious adverse event related to study drugOverall population, N = 44, No. (%)
Any serious adverse event related to study drug“4 (9.1)”
Diarrhea“1 (2.3)”
Pulmonary embolism“1 (2.3)”
Syncope“1 (2.3)”
Sudden death“1 (2.%)”
HLA-A∗02:01-positive expansion, overall population: treatment-related adverse events
Adverse eventOverall, N = 101, n (%)
Related adverse event“101 (100)”
Related serious adverse event“12 (11.9)”
Related grade 3 or higher adverse event“38 (37.6)”
Related adverse event leading to discontinuation“9 (8.9)”
Related adverse events leading to reduction“28 (27.7)”
Diarrhea“83 ( 82.2)”
Nausea“77 ( 76.2)”
Edema peripheral“71 ( 70.3)”
Vomiting“58 ( 57.4)”
Fatigue“55 ( 54.5)”
Dizziness“38 ( 37.6)”
Dermatitis acneiform“35 ( 34.7)”
Hypotension“33 ( 32.7)”
Study limitations
Summary

The OptimUM-01 first-line cohort is an open-label, single-arm, nonrandomized expansion of 44 participants, of whom 41 were efficacy-evaluable; the authors describe the data as hypothesis-generating. No formal hypothesis testing was prespecified, and all results were summarized descriptively. Response was assessed by the investigator per RECIST version 1.1. The efficacy-evaluable population required at least one post-baseline tumor assessment, which excluded two participants who discontinued before assessment (one for sudden death) and one ongoing participant; PFS and OS were measured from the first day of treatment in the safety population, and OS is an exploratory end point. The authors state that PFS and OS results are preliminary and that the proportion censored and the medians will change with longer follow-up. Disease control was defined as stable disease lasting at least 8 weeks, where OptimUM-02 required at least 12 weeks. The HLA-A∗02:01 subgroups comprise 29 HLA-A∗02:01-negative and 10 HLA-A∗02:01-positive evaluable participants, and HLA status was unknown for about 5% because testing was not routinely performed at enrollment. Molecular response could be assessed in only the 20 participants with driver mutations reported from tumor tissue. The study reports no quality-of-life or patient-reported outcome results; its end points were safety, ORR, duration of response, disease control rate, PFS, and OS. Comparisons with historical data sets carry, in the authors' words, “the necessary caveats and limitations of cross-study comparisons”.

In the HLA-A∗02:01-positive expansion, response was assessed in an efficacy-evaluable population of participants with at least 3 post-baseline assessments or who discontinued treatment, giving denominators of 11 of 13 treatment-naive and 86 of 101 overall participants. IDEAYA's earlier phase 2 results for 68 participants receiving the combination (data cutoff August 22, 2023) were preliminary and based on investigator review from an unlocked database.

Within the first-line cohort publication, the 95% CIs for median PFS (3.8 to 7.7 months in the results; 5.0 to 8.3 months in the abstract) and median OS (12.5 to 27.1 months; 11.9 to 20.7 months) differ, as do the ORR in HLA-A∗02:01-positive participants (30.0%, 3 of 10, in the subgroup table; 40% in the discussion), the incidence of diarrhea (95.5%; 95.2%), and the incidence of hypotension (18.3%; 18.2%).